These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 17220241

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Characterization of two cyclic metabolites of sitagliptin.
    Liu DQ, Arison BH, Stearns RA, Kim D, Vincent SH.
    Drug Metab Dispos; 2007 Apr; 35(4):521-4. PubMed ID: 17220240
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R.
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
    Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA.
    J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
    [Abstract] [Full Text] [Related]

  • 7. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE.
    J Med Chem; 2005 Jan 13; 48(1):141-51. PubMed ID: 15634008
    [Abstract] [Full Text] [Related]

  • 8. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
    Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman G.
    J Clin Pharmacol; 2007 Feb 13; 47(2):165-74. PubMed ID: 17244767
    [Abstract] [Full Text] [Related]

  • 9. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A, Mistry GC, Luo WL, Liu Q, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman GA, Wagner JA, Krishna R.
    Biopharm Drug Dispos; 2007 Sep 13; 28(6):307-13. PubMed ID: 17571284
    [Abstract] [Full Text] [Related]

  • 10. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA, Bergman A, Yi B, Kipnes M, Sitagliptin Study 012 Group.
    Curr Med Res Opin; 2006 Oct 13; 22(10):1939-47. PubMed ID: 17022853
    [Abstract] [Full Text] [Related]

  • 11. Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs.
    Beconi MG, Mao A, Liu DQ, Kochansky C, Pereira T, Raab C, Pearson P, Lee Chiu SH.
    Drug Metab Dispos; 2003 Oct 13; 31(10):1269-77. PubMed ID: 12975337
    [Abstract] [Full Text] [Related]

  • 12. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
    Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA.
    J Clin Pharmacol; 2007 Feb 13; 47(2):159-64. PubMed ID: 17244766
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
    Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CG, Kao M, Kelley MF, Meuldermans W.
    Drug Metab Dispos; 2007 Apr 13; 35(4):566-75. PubMed ID: 17220243
    [Abstract] [Full Text] [Related]

  • 15. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH, Painter SK, Luffer-Atlas D, Karanam BV, McGowan E, Cioffe C, Doss G, Chiu SH.
    Drug Metab Dispos; 1997 Aug 13; 25(8):932-9. PubMed ID: 9280401
    [Abstract] [Full Text] [Related]

  • 16. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ.
    Drug Metab Dispos; 2009 Aug 13; 37(8):1738-48. PubMed ID: 19420130
    [Abstract] [Full Text] [Related]

  • 17. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C, Cui D.
    Drug Metab Dispos; 1997 Dec 13; 25(12):1395-406. PubMed ID: 9394030
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, Humphreys WG, Kirby M.
    Drug Metab Dispos; 2009 Jun 13; 37(6):1164-71. PubMed ID: 19251818
    [Abstract] [Full Text] [Related]

  • 20. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C, Soliman V.
    Drug Metab Dispos; 1997 Nov 13; 25(11):1288-97. PubMed ID: 9351906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.